Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

The Mounjaro buzz is now distinctly reaching Indian A-listers and wellness-conscious urban adults, sparking conversations about its potential ...

Patients regain weight after stopping weight loss drugs, long-term success may depend on lifestyle and drug choice.

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo Nordisk and UnitedHealth Group have been beaten down to less than half their ...

PARIS, France I July 21, 2025 I Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in ...